Sep. 2 at 9:17 PM
$PRME "We expect an I&D for Wilson's Disease in the first half of next year. Alpha-1, just a little bit after that, in the middle of next year. And data for both programs expected in 2027. So 2027 becomes a really impactful year, as you think about value creation for the company. If I think about sort of medium term, we've got Cystic Fibrosis. That we're working on. That's being, you know, predominantly funded by the Cystic Fibrosis Foundation. We're going after both many of the mutations that are not amenable to current standard of care. And ultimately, we think we can treat, you know, with a handful of editors 93 plus percent of the CF population."
